CellCentric company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cellcentric.com

Founded Year

2004

Stage

Series F | Alive

Total Raised

$73.9M

About CellCentric

CellCentric is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for prostate (CRPC) and other cancers.

CellCentric Headquarter Location

Chesterford Research Park Little Chesterford

Cambridge, England, CB10 1XL,

United Kingdom

+44 (0) 1799 531130

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CellCentric

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CellCentric is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CellCentric Patents

CellCentric has filed 10 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Proteins
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/18/2017

6/30/2020

Transcription factors, Experimental cancer drugs, Proteins, Oncology, Epigenetics

Grant

Application Date

10/18/2017

Grant Date

6/30/2020

Title

Related Topics

Transcription factors, Experimental cancer drugs, Proteins, Oncology, Epigenetics

Status

Grant

Latest CellCentric News

CellCentric Strengthens Leadership Team

Apr 6, 2022

Share this article Share this article Kris Frese formerly Co-Lead at the Cancer Biomarker Centre Preclinical Pharmacology Team at Cancer Research UK, joins as Director of Cancer Biology Andrew Hughes, Chief Development Adviser, who has led over 50 oncology R&D programmes at AstraZeneca, joins the Board CAMBRIDGE, England, April 6, 2022 /PRNewswire/ -- CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces the appointments of Kris Frese as Director of Cancer Biology, and Andrew Hughes, who joins the Board as a Non-Executive Director. Both have stellar experience and track records in oncology research and development. CellCentric is developing inobrodib, an orally bioavailable drug that is transitioning into Phase II clinical trials in multiple indications. The first-in-class small molecule p300/CBP inhibitor that has the potential to treat a number of established but difficult to treat oncogenes. Kris Frese is an experienced cancer biologist who specialises in models of cancer and biomarker analysis. Kris most recently served as an Associate Scientist at Cancer Research UK where he co-led the Cancer Biomarker Centre Preclinical Pharmacology Team. Andrew Hughes, who has acted as Chief Development Adviser to the company to date, has more than 25 years' experience of oncology clinical development in biotechnology and pharmaceutical companies. He previously led over 50 oncology research and development programmes of novel drug candidates at AstraZeneca Pharmaceuticals. Andrew is also Honorary Professor of Experimental Cancer Medicine at The University of Manchester and has a strong track record of executing clinical development programmes, resulting in successful product registrations. Kris Frese, Director of Cancer Biology of CellCentric said: "I am excited to join CellCentric at this stage of development. I have been impressed by the comprehensive research and compelling early clinical data in the treatment of different indications of cancer. I look forward to working closely with the team to maximise the potential of inobrodib to deliver improved treatments for people with cancer." Andrew Hughes, Chief Development Adviser and Board Member of CellCentric, commented: "Inobrodib is a highly-differentiated, first-in-class compound with a novel mechanism of action. It can treat different indications of cancer, including both solid tumours and haematological cancers. My experience in executing expanding clinical development programmes, leading to successful product registrations, can help to further progress inobrodib's development." Will West, Chief Executive Officer of CellCentric added: "CellCentric is entering an exciting stage as it begins to transition to Phase II clinical trials of inobrodib. Our vision is to make a real difference to the lives of people with cancer which we can only deliver with an excellent team of highly experienced, motivated people. Both Kris and Andrew have a wealth of knowledge in oncology and clinical development that will be invaluable to accelerate the further development of inobrodib in multiple specific clinical settings." About CellCentric CellCentric is a research driven and patient-centric clinical stage, private biotechnology company pioneering small molecule inhibition of the twin proteins, p300/CBP. It is focused on the rapid development of inobrodib, a first-in-class small molecule p300/CBP inhibitor, which has the potential to benefit patients with many different cancer indications. Inobrodib is in clinical trials to evaluate its effectiveness to treat late-stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers. These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives. CellCentric is privately held; its lead investor is Boston based, Morningside Ventures. Find out more: https://www.cellcentric.com/  SOURCE CellCentric

CellCentric Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CellCentric Rank

  • When was CellCentric founded?

    CellCentric was founded in 2004.

  • Where is CellCentric's headquarters?

    CellCentric's headquarters is located at Chesterford Research Park, Cambridge.

  • What is CellCentric's latest funding round?

    CellCentric's latest funding round is Series F.

  • How much did CellCentric raise?

    CellCentric raised a total of $73.9M.

  • Who are CellCentric's competitors?

    Competitors of CellCentric include Cognition Therapeutics, FORMA Therapeutics, Prosarix, Proteostasis Therapeutics, Peakdale Molecular and 11 more.

You May Also Like

P
Priaxon

Priaxon is a research company focusing on drug discovery for small molecule therapeutics.

I
IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

S
Syntopix

Syntopix is a specialised research and development business, focusing on the discovery of topical antimicrobials for healthcare and pharmaceutical applications through the repositioning of known chemical entities that have a history of use in humans.nThe company seek to identify compounds and develop products that treat dermatological conditions, principally acne and topical staphylococcal infections, including those due to MRSA.nThe company's antimicrobial expertise is now also being successfully applied to other areas as the company develop collaborative relationships with major healthcare companies.

I
InVasc Therapeutics

InVasc Therapeutics specializes in target-specific drug discovery and has developed a approach to drug discovery that uses molecular structures and an application-based platform that decreases the time and expense of current large-scale "mining"� discovery techniques. The InVasc process is the result of university-based research at Emory University and The Ohio State University.

L
Lead Therapeutics

LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule pre-IND candidates against clinically validated therapeutic targets by leveraging the best of the US and China. Headquartered in the San Francisco Bay Area, LEAD Therapeutics is led by an experienced small molecule drug discovery team with proven track records in the pharmaceutical and biotech industries. The company plans to carry out the majority of its discovery research activities in China.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.